{"id":71706,"date":"2026-08-05T13:33:26","date_gmt":"2026-08-05T05:33:26","guid":{"rendered":"https:\/\/flcube.com\/?p=71706"},"modified":"2026-08-05T13:33:27","modified_gmt":"2026-08-05T05:33:27","slug":"innovent-biologics-reports-h1-2026-revenue-exceeding-rmb-8-2-billion-up-55-year-over-year","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71706","title":{"rendered":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Innovent Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1801:HKG\">HKG: 1801<\/a>) today announced its product revenue for the first half of 2026, reporting <strong>product revenue exceeding RMB 8.2 billion<\/strong> ($1.14 billion), representing a <strong>year\u2011over\u2011year increase of over 55%<\/strong>. Second quarter product revenue reached <strong>over RMB 4.3 billion<\/strong>, up approximately <strong>60% year\u2011over\u2011year<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-snapshot\" class=\"wp-block-heading\">Financial Performance Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Product Revenue<\/strong><\/td><td>RMB 8.2B+<\/td><td>+55%+<\/td><\/tr><tr><td><strong>Q2 Product Revenue<\/strong><\/td><td>RMB 4.3B+<\/td><td>+60%<\/td><\/tr><tr><td><strong>Growth Driver<\/strong><\/td><td>Core product portfolio<\/td><td>Strong momentum across all segments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-core-product-portfolio-highlights\" class=\"wp-block-heading\">Core Product Portfolio Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mazdutide injection<\/strong>: Exceptional market performance in metabolic disorders<\/li>\n\n\n\n<li><strong>Tafolecimab injection<\/strong>: Strong uptake in oncology indications<\/li>\n\n\n\n<li><strong>Teprotumumab N01 injection<\/strong>: Rapid adoption in ophthalmology applications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These core products have emerged as the <strong>primary drivers of revenue growth<\/strong>, demonstrating Innovent&#8217;s successful commercialization strategy and market penetration across multiple therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-global-innovation-pipeline-advancement\" class=\"wp-block-heading\">Global Innovation Pipeline Advancement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Global Trials<\/strong>: Three core innovative assets advancing to late-stage development<\/li>\n\n\n\n<li><strong>Therapeutic Expansion<\/strong>: Next-generation pipeline spanning:<\/li>\n\n\n\n<li>Oncology<\/li>\n\n\n\n<li>Cardiovascular and Metabolism (CVM)<\/li>\n\n\n\n<li>Autoimmunity<\/li>\n\n\n\n<li>Ophthalmology<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The company continues to strengthen its position as a global biopharmaceutical innovator with a diversified pipeline addressing high-value therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-strategic-collaborations-amp-partnerships\" class=\"wp-block-heading\">Strategic Collaborations &amp; Partnerships<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Type<\/th><th>Count<\/th><th>Key Partners<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Collaborations<\/strong><\/td><td>20+<\/td><td>Pfizer, Eli Lilly, Takeda, Roche<\/td><\/tr><tr><td><strong>Co-Development &amp; Co-Commercialization (Co-Co)<\/strong><\/td><td>5<\/td><td>Multinational pharmaceutical leaders<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">These strategic alliances validate Innovent&#8217;s innovative capabilities and provide multiple pathways for global commercialization of its pipeline assets.<\/p>\n\n\n\n<h2 id=\"h-market-outlook-amp-forward-strategy\" class=\"wp-block-heading\">Market Outlook &amp; Forward Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Trajectory<\/strong>: On track to exceed full-year 2026 guidance based on H1 performance<\/li>\n\n\n\n<li><strong>Pipeline Catalysts<\/strong>: Multiple potential regulatory submissions expected in 2027\u20132028<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Increasing focus on international markets through partnership models<\/li>\n\n\n\n<li><strong>R&amp;D Investment<\/strong>: Continued allocation of resources to next-generation innovation across core therapeutic areas<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, pipeline development, and strategic partnerships. Actual results may differ due to risks including regulatory approvals, market competition, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080500054_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080500054_c.\"><\/object><a id=\"wp-block-file--media-bfcf844a-8675-4d6c-9e9a-670c270acdd4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080500054_c.pdf\">2026080500054_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080500054_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bfcf844a-8675-4d6c-9e9a-670c270acdd4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71708,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,910,198],"class_list":["post-71706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026, reporting product revenue exceeding RMB 8.2 billion ($1.14 billion), representing a year\u2011over\u2011year increase of over 55%. Second quarter product revenue reached over RMB 4.3 billion, up approximately 60% year\u2011over\u2011year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71706\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71706\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T05:33:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T05:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year\",\"datePublished\":\"2026-08-05T05:33:26+00:00\",\"dateModified\":\"2026-08-05T05:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706\"},\"wordCount\":309,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0501.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71706#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71706\",\"name\":\"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0501.webp\",\"datePublished\":\"2026-08-05T05:33:26+00:00\",\"dateModified\":\"2026-08-05T05:33:27+00:00\",\"description\":\"Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026, reporting product revenue exceeding RMB 8.2 billion ($1.14 billion), representing a year\u2011over\u2011year increase of over 55%. Second quarter product revenue reached over RMB 4.3 billion, up approximately 60% year\u2011over\u2011year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71706\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71706#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026, reporting product revenue exceeding RMB 8.2 billion ($1.14 billion), representing a year\u2011over\u2011year increase of over 55%. Second quarter product revenue reached over RMB 4.3 billion, up approximately 60% year\u2011over\u2011year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71706","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=71706","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T05:33:26+00:00","article_modified_time":"2026-08-05T05:33:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71706#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71706"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year","datePublished":"2026-08-05T05:33:26+00:00","dateModified":"2026-08-05T05:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71706"},"wordCount":309,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71706#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","keywords":["Finanical Reports","HKG: 1801","Innovent Biologics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71706#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71706","url":"https:\/\/flcube.com\/?p=71706","name":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71706#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71706#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","datePublished":"2026-08-05T05:33:26+00:00","dateModified":"2026-08-05T05:33:27+00:00","description":"Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026, reporting product revenue exceeding RMB 8.2 billion ($1.14 billion), representing a year\u2011over\u2011year increase of over 55%. Second quarter product revenue reached over RMB 4.3 billion, up approximately 60% year\u2011over\u2011year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71706#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71706"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71706#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","width":1080,"height":608,"caption":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71706#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year\u2011Over\u2011Year"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71706"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71706\/revisions"}],"predecessor-version":[{"id":71709,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71706\/revisions\/71709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71708"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}